<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00647205</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS EP 40 QUANTI SPOT</org_study_id>
    <nct_id>NCT00647205</nct_id>
  </id_info>
  <brief_title>Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT</brief_title>
  <official_title>Evaluation of 2 Interferon γ Assays (QuantiFERON TB Gold In-Tube® and T-SPOT.TB®) in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Agency for Research on AIDS and Viral Hepatitis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French National Agency for Research on AIDS and Viral Hepatitis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to estimate the usefulness of QuantiFERON TB Gold In-Tube® and
      T-SPOT.TB® for the diagnosis of latent tuberculosis in HIV infected antiretroviral naive
      patients: 80 originated from low TB prevalence countries, without any active TB; 80 HIV
      infected antiretroviral naïve patients originated from high TB prevalence countries, without
      any active TB, 40 HIV infected patients with active TB and 40 HIV negative patients with
      active TB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to estimate the usefulness of QuantiFERON TB Gold In-Tube and
      T-SPOT.TB for the diagnosis of latent tuberculosis in this population. Concordance between
      TST, QuantiFERON TB Gold and T-SPOT.TB will be assessed in patients with different risks of
      TB, in a transversal study. This study will include 240 patients during 2 years: 80 HIV
      infected antiretroviral naïve patients originated from low TB prevalence countries, without
      any active TB (40 patients with CD4 cell count &gt; 350/mm3, 40 with CD4 &lt; 350/mm3), 80 HIV
      infected antiretroviral naïve patients originated from high TB prevalence countries, without
      any active TB, 40 HIV infected patients with active TB and 40 HIV negative patients with
      active TB. TST and the 2 blood interferon gamma assay will be compared according to the level
      of risk. The improvement of latent TB diagnosis in HIV infected patients may lead to the
      initiation of TB prophylaxis and decrease the incidence of this life threatening disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intradermal Tuberculin Tests QuantiFERON TB Gold In-Tube® T-SPOT.TB®</measure>
    <time_frame>48 to 72 hours after the injection</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>HIV Infections</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>HIV infected antiretroviral naïve patients originated from low TB prevalence countries without any active TB with CD4 cell count &gt; 350/mm3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>HIV infected antiretroviral naïve patients originated from low TB prevalence countries without any active T with CD4 &lt; 350/mm3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>HIV infected antiretroviral naïve patients originated from high TB prevalence countries without any active TB with CD4 &lt; 350/mm3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>HIV infected antiretroviral naïve patients originated from high TB prevalence countries without any active TB with CD4 &gt; 350/mm3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>HIV infected patients with active TB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>HIV negative patients with active TB</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>QuantiFERON TB Gold In-Tube</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>T-SPOT.TB®</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  sign an informed consent

          -  to be adult

          -  not to be pregnant

          -  to have a clinical examination and a medical questionnaire

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Bonnet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>France Mentre, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses B Hopital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2008</study_first_posted>
  <last_update_submitted>August 8, 2011</last_update_submitted>
  <last_update_submitted_qc>August 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Marcia Trumeau regulatory</name_title>
    <organization>ANRS</organization>
  </responsible_party>
  <keyword>Interferon, gamma</keyword>
  <keyword>HIV Infections</keyword>
  <keyword>Tuberculosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

